Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC

INTRODUCTION: Programmed cell death 1 (PD-1) inhibitors have become standard treatment for patients with advanced NSCLC. However, few studies have focused on the impact of cancer cachexia on the efficacy of PD-1 or programmed death-ligand 1 (PD-L1) inhibitors among patients with NSCLC. METHODS: We r...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyawaki, Taichi, Naito, Tateaki, Kodama, Akihro, Nishioka, Naoya, Miyawaki, Eriko, Mamesaya, Nobuaki, Kawamura, Takahisa, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Notsu, Akifumi, Mori, Keita, Harada, Hideyuki, Endo, Masahiro, Takahashi, Kazuhisa, Takahashi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474252/
https://www.ncbi.nlm.nih.gov/pubmed/34589927
http://dx.doi.org/10.1016/j.jtocrr.2020.100020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474252/
https://www.ncbi.nlm.nih.gov/pubmed/34589927
http://dx.doi.org/10.1016/j.jtocrr.2020.100020

Ejemplares similares